| 主权项 |
1. A chemical entity of Formula (I):wherein:Z is CH or N;i) wherein when Z is CH, then;R1 is a member selected from the group consisting of: —H, —C1-3alkyl and —C1-3haloalkyl;Y is —C(Ra)2—, where each Ra is independently selected from the group consisting of: —H, —F, —CH3, —OH and —N(Rb)2;R2 is a member selected from the group consisting of:
A) phenyl unsubstituted or substituted with one or two Rc members, where each Rc is independently selected from the group consisting of: halo, —CN, —CO2Rb, —CONH2, —SO2CH3, —C(Rb)2OH, —CH2NH2, —CH2CONH2, —CH2CO2C1-3alkyl, —NHCONH2, —NHCONH-oxetane, —CONH-oxetane, B) six-membered monocyclic heteroaromatic ring containing one or two nitrogen members unsubstituted or substituted with one or two members each independently selected from the group consisting of: halo, —C1-3alkyl, —C1-3haloalkyl, —CN, —OH, —C(Rb)2OH, —CH2NH2, —C(Rb)2CN, —C(Rb)2CONH2, —OCH2CONH2, —OC1-3alkyl, —OCH2C(Rb)2OH, —OCH2cyclopropyl, —OC1-3haloalkyl, —CO2H, —CON(Rb)2, —N(Rb)2, —NHCH2CF3, —NHCH(CH3)2, —NHCH2CH2N(CH3)2, —NHCH2CH2OH, —NHcyclopropyl, —NHCOCH3, morpholinyl, pyrrolidin-3-ol, and azetidin-3-ol; C) five-membered monocyclic heteroaromatic ring containing two, three, or four nitrogen members unsubstituted or substituted with one or two members each independently selected from the group consisting of halo, —C1-3alkyl, —C1-3haloalkyl, —C(Rb)2OH, —N(Rb)2, —NO2, —CN, —CH2CN, —OC1-3alkyl, —CH2OCH3, —CH2CH2OH, —CH2NH2, —CH2CONH2, —CO2C1-3alkyl, —CO2H, —CONH2, —NHCOCH3, and cyclopropyl; and D) five or six-membered ring selected from: 1,2-dihydro-pyridin-2-one, thiazole or 1,2-oxazole unsubstituted or substituted with one or two members each independently selected from the group consisting of —CH3, and —NH2;R3 is phenyl or pyridine, each substituted with one or two members each independently selected from the group consisting of: -halo, —C1-3alkyl, —OC1-3alkyl, —Ocyclopropyl, —O-oxetane, —C1-3haloalkyl, —OC1-3haloalkyl, —CN, —CH2OH, —SO2CH3, or —N(CH3)2;R4 is a member selected from the group consisting of —C1-3alkyl and —C1-3haloalkyl; andeach Rb is independently selected from —H or —CH3;ii) wherein when Z is N, then;R1 is —H;Y is —CH2—;R2 is a member selected from the group consisting of:
A) phenyl substituted with one or two Rd members, where each Rd is independently selected from the group consisting of: —CN, —CONH2, and —CO2C1-3alkyl; B) six-membered monocyclic heteroaromatic ring containing one or two nitrogen members unsubstituted or substituted with a member selected from the group consisting of: —CN, —OC1-3alkyl, —CONH2, —NHCH2CH2OH, —N(Rb)2, and —NH-cyclopropyl; C) five-membered monocyclic heteroaromatic ring containing two or three nitrogen members unsubstituted or substituted with one or two members each independently selected from the group consisting of —C1-3alkyl, —C1-3haloalkyl, —CH2ORb, —N(Rb)2, —NO2, —CO2CH3, —CO2N(Rb)2, or cyclopropyl; and D) 1,2-oxazole optionally substituted with one or two Rb members;R3 phenyl substituted with one or two members each independently selected from the group consisting of: —Cl, —OC1-3alkyl, or —OC1-3haloalkyl;R4 is —C1-3alkyl; andeach Rb is independently selected from —H or —CH3;wherein the chemical entity is selected from the group consisting of compounds of Formula (I), pharmaceutically acceptable salts of compounds of Formula (I), pharmaceutically acceptable prodrugs of compounds of Formula (I); and pharmaceutically active metabolites of compounds of Formula (I). |
